Open AccessRationale for Dose Selection for Carbavance ([CVC] Meropenem/RPX7009) in Phase 3 Trials
Author(s) -
Olga Lomovskaya,
David C. Griffith,
Jeff Loutit,
Michael Dudley
Publication year - 2015
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofv133.511
Subject(s) - meropenem , medicine , selection (genetic algorithm) , piperacillin/tazobactam , intensive care medicine , antibiotics , artificial intelligence , microbiology and biotechnology , piperacillin , computer science , antibiotic resistance , biology , genetics , bacteria , pseudomonas aeruginosa
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom